The Effect of Soluble Complement Receptor 1 (sCR1) and Human Thyroid Antibodies on the Course of Experimental Autoimmune Thyroiditis in Rats

References

• Werner S. C., Wigelius O., Fierer J. A., Hsu K. C. Immunoglobulins (E., M., G.) and complement in the connective tissue of the thyroid in Graves' disease. N. Engl. J. Med. 1972; 287: 421–424
   PubMed Web of Science ®Google Scholar
• Kalderon A. E., Boggars H. A. Immune complexes deposits in Graves' disease and Hashimoto's thyroiditis. Am. J. Med. 1977; 63: 729–734
   PubMedGoogle Scholar
• Oleesky D. A., Ratanachaiyavong S., Ludgate M., Morgan B. P., Campbell A. K., McGregor A. M. Complement component C9 in Graves' disease. Clin. Endocrinol 1986; 25: 623–632
   PubMedGoogle Scholar
• Weetman A. P., Cohen S. B., Oleesky D. A., Morgan B. P. Terminal complement complexes and C1/C1 inhibitor complexes in autoimmune thyroid disease. Clin. Exp. Immunol. 1989; 77: 25–30
   PubMed Web of Science ®Google Scholar
• Tandon N., Morgan B. P., Weetman A. P. Expression and function of membrane attack complex inhibitory proteins on thyroid follicular cells. Immunology 1992; 75: 372–377
   PubMedGoogle Scholar
• Tandon N., Yan S. L., Morgan B. P., Weetman A. P. Expression and function of multiple regulators of complement activation in autoimmune thyroid disease. Immunology 1994; 81: 643–647
   PubMedGoogle Scholar
• Weetman A. P., Freeman M., Morgan B. P. Thyroid follicular cell function after non-lethal complement membrane attack. Clin. Exp. Immunol. 1990; 82: 69–74
   PubMedGoogle Scholar
• Weetman A. P., Tandon N., Morgan B. P. Antithyroid drugs and release of inflammatory mediators by complement-attacked thyroid cells. Lancet 1992; 340: 633–636
   PubMed Web of Science ®Google Scholar
• Inoue K., Niesen N., Milgrom F., Albini B. Transfer of experimental autoimmune thyroiditis by in situ perfusion of thyroid with immune sera. Clin. Immunol. Immunopathol 1993; 66: 11–17
   PubMedGoogle Scholar
• Inoue K., Niesen N., Biesecker G., Milgrom F., Albini B. Role of late complement components in experimental autoimmune thyroiditis. Clin. Immunol. Immunopathol 1993; 66: 1–10
   PubMedGoogle Scholar
• Rennie D. P., McGregor A. M., Keast D., Weetman A. P., Foord S. M., Dieguez C., Williams E. D., Hall R. The influence of methimazole on thyroglobulin-induced autoimmune thyroiditis in the rat. Endocrinology 1984; 112: 326–330
   Google Scholar
• Rosem N. R., Shulman S., Witebsky E. Studies on organ specificity. XIII. Immunological analysis of thyroglobulin and thyralbumin. J. Immunol. 1962; 88: 229–239
   PubMedGoogle Scholar
• Roitt I. M., Jones H. E., Mills G. L. The activity of different fractions of homologous thyroid extract in the production of allergic thyroiditis in the rat. Immunology 1965; 9: 281–286
   PubMedGoogle Scholar
• Piddlesden S. J., Storch M. K., Hibbs M., Freeman A. M., Lassman H., Morgan B. P. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. Am. Assoc. Immunol. 1994; 152: 5477–5484
   Google Scholar
• Feardon D. T. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc. Natl Acad. Sci. USA 1979; 76: 5867–5871
   PubMedGoogle Scholar
• Yoon S., Fearon D. T. Characterisation of a soluble form of the C3b/C4b receptor (CR1) in human plasma. J. Immunol. 1985; 134: 3332–3338
   PubMed Web of Science ®Google Scholar
• Wiesman H. F., Bartow T., Leppo M. K., Marsh H. C., Jr., Carson G. R., Concino M. F., Boyle M. P., Roux K. H., Weisfeldt M. L., Fearon D. T. Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990; 249: 146–151
   PubMedGoogle Scholar
• Morgan B. P. Clinical complementology: recent progress and future trends. Eur. J. Clin. Invest. 1994; 24: 219–228
   PubMedGoogle Scholar
• Hill J., Lindsay T. F., Ortiz F., Yeh C. G., Hechtman H. B., Moore F. D., Jr. Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat. J. Immunol. 1992; 149: 1723–1728
   PubMed Web of Science ®Google Scholar
• Xia W., Fearon D. T., Moore F. D., Jr., Schoen F. J., Ortiz F., Kirkman R. L. Prolongation of guinea pig cardiac xenograft survival in rats by soluble human complement receptor type 1. Transplant Proc. 1992; 24: 479–480
   PubMed Web of Science ®Google Scholar
• Rose N. R., Molotchnikoff M.-F., Twarog F. J. Factors affecting transfer of experimental autoimmune thyroiditis in rats. Immunology 1973; 24: 859–870
   PubMedGoogle Scholar
• Nakamura R. M., Weigle W. O. Transfer of experimental autoimmune thyroiditis by serum from thyroi-dectomized donors. J. Exp. Med. 1969; 130: 263–285
   PubMedGoogle Scholar
• Tomazik V., Rose N. R. Autoimmune murine thyroiditis VII: Induction of the thyroid lesions by passive transfer of immune serum. Clin. Immunol. Immunopathol 1975; 4: 511–518
   PubMedGoogle Scholar
• Rayfield L. S., Smith T. A., Andrews S. J., Bergmeier L. A. Induction of experimental autoimmune thyroiditis in B cell-depleted mice. Immunol. Lett. 1989; 20: 21–27
   PubMedGoogle Scholar
• Vladutiu A. O. Experimental autoimmune thyroiditis in mice chronically treated from birth with anti-IgM antibodies. Cell Immunol. 1989; 121: 49–59
   PubMedGoogle Scholar
• Adler T. R., Beall G. N., Curd J. G., Heiner D. C., Sabharwal U. K. Studies of complement activation and IgG subclass restriction of anti-thyroglobulin. Clin. Exp. Immunol. 1984; 56: 383–389
   PubMedGoogle Scholar
• Cohen S. B., Weetman A. P. Serological analysis of experimental autoimmune thyroiditis in the Buffalo strain rat. Int. Arch. Allergy Appl. Immunol. 1990; 91: 47–53
   PubMedGoogle Scholar
• Kofler H., Kofler R., Wolf H., Wick G. Immunofluorescence studies on the co-distributions immune deposits and complement in the thyroid glands of Obese strain (OS) chickens. Immunobiology 1983; 164: 390–401
   PubMed Web of Science ®Google Scholar
• Rose N. R., Molotchnikoff M.-F. Variations in complement levels during active and adoptive immunization. J. Immunol. 1973; 110: 867–872
   PubMedGoogle Scholar
• Piddlesden S. J., Storch M. K., Hibbs M., Freeman A. M., Lassmann H., Morgan B. P. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J. Immunol. 1994; 152: 5477–5484
   PubMed Web of Science ®Google Scholar
• Mathieson P. W., Qasim F. J., Thiru S., Oldroyd R. G., Oliveira D. B. G. Effects of decomplementation with cobra venom factor on experimental vasculitis. Clin. Exp. Immunol. 1994; 97: 474–477
   PubMedGoogle Scholar
• Baxter A. G., Cooke A. Complement lytic activity has no role in the pathogenesis of autoimmune diabetes in NOD mice. Diabetes 1993; 42: 1574–1578
   PubMed Web of Science ®Google Scholar
• Sharp G. C., Words H. H., Dunmore B. The biological effects of anti-thyroid antibodies. Thyroid eosinophilia following passive transfer of anti-thyroglobulin antibody. Immunol. 1967; 13: 39–48
   PubMedGoogle Scholar